Comparative Pharmacology
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus U CORT.
CLOCORTOLONE PIVALATE vs U-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clocortolone pivalate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Topical: Apply a thin film to affected area once or twice daily. Not for ophthalmic use. Maximum duration of 2 weeks per course.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 1-4 hours), reflecting rapid clearance; clinical duration exceeds half-life due to tissue binding.
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Primarily renal (approximately 80%) as glucuronide and sulfate conjugates; minor biliary/fecal excretion (20%).
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid